

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1.- 36. (cancelled)

31496  
37. (currently amended) A method for treating a mammal comprising administering a therapeutically effective amount of a stable reconstituted formulation to the mammal in order to treat ~~a disorder selected from the group consisting of~~ an IgE-mediated allergic disease ~~, a parasitic infection, interstitial cystitis and asthma~~ in the mammal, wherein the reconstituted formulation comprises an antibody which binds IgE in an amount of 50 mg/mL to about 400mg/mL and has been prepared by reconstituting a lyophilized mixture of the antibody and a lyoprotectant in a diluent, wherein the antibody concentration in the reconstituted formulation is about 2-40 times greater than the antibody concentration in the mixture before lyophilization.

38. (previously presented) The method of claim 37 wherein the formulation is administered subcutaneously.

39. (previously presented) The method of claim 37 wherein the mammal is a human.

40.-43. (cancelled)

44. (previously presented) The method of claim 39 wherein about 1-15 mg/kg of the antibody is administered to the human.

31-496  
45. (previously presented) A method for treating a mammal comprising administering a therapeutically effective amount of a formulation to the mammal in order to treat an IgE-mediated allergic disease in the mammal, wherein the formulation comprises an antibody which binds IgE in an amount of 50 mg/mL to about 400mg/mL.

46. (New) The method of claim 45 wherein the formulation comprises the IgE antibody in an amount of 80 mg/mL to about 300mg/mL.

47. (New) The method of claim 45 wherein the antibody is administered subcutaneously.

48. (New) The method of claim 45 wherein the mammal is a human.

49. (New) A method for treating a human comprising administering subcutaneously a therapeutically effective amount of a formulation to the human in order to treat an IgE-mediated allergic disease in the human, wherein the formulation comprises an antibody which binds IgE in an amount in the range from 80 mg/mL to about 300mg/mL.